Glepaglutide (Zeydovio)
Zeydovio is indicated for the treatment of adults with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.
In 106 adults with short bowel syndrome and intestinal failure, glepaglutide twice weekly cut weekly parenteral support volume more than placebo at 24 weeks (mean −5.13 vs −2.85 L/wk; P=.0039); once-weekly dosing showed no significant benefit. RCT · phase 3 · n = 106 · Gastroenterology · 2024
Secondary analysis (exit interviews) of a phase 3 trial in 30 patients with short bowel syndrome with intestinal failure: 73% (16/22) on glepaglutide vs 25% (2/8) on placebo reported better health-related quality of life; descriptive, small numbers. Secondary analysis · phase 3 · n = 30 · Nutr Clin Pract · 2026